Custom Phospho-Specific Antibody Production Service
Drawing upon many years’ experience, AMSBIO has developed a custom phospho-specific antibody production service that is both reliable and produces highly specific quality antisera.
Phospho-specific antibodies are widely accepted for use in defining regulatory mechanisms that control cell functions such as activation of enzymes and receptors, cellular transcription, signal transduction, and cell signalling networks. Phospho-specific antibodies from AMSBIO are affinity-purified rabbit polyclonal or monoclonal antibodies that are monospecific for a target protein that is phosphorylated on a specific tyrosine, threonine or serine residue.
AMSBIO’s custom phospho-specific polyclonal antibody service includes synthesis of phosphorylated and non-phosphorylated peptides, conjugation to a carrier protein, immunization and anti-sera production. All antibodies are then purified using a two-step immuno-affinity method. The purified phospho-specific antibody is fully characterised using both dot-blot and ELISA techniques to ensure product of the highest consistency and quality. Hundreds of custom phospho specific antibodies have been successfully made by AMSBIO and supplied to leading international research groups [1,2].
References
1. C.J. Cox, et al., 'Brain Human Monoclonal Autoantibody from Sydenham Chorea Targets Dopaminergic Neurons in Transgenic Mice and Signals Dopamine D2 Receptor: Implications in Human Disease,' The Journal of Immunology (2013).
2. K.M. Brown, et al., 'Cyclic AMP-Specific Phosphodiesterase, PDE8A1, is Activated by Protein Kinase A-Mediated Phosphorylation,' Febs Letters, 586(11), 1631–1637, Elsevier (2012).
Related News
-
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs... -
News Chasing new frontiers at LEAP – The National Biotechnology Strategy Keynote
On the third day of LEAP (4–7 March 2024, Riyadh Exhibition and Convention Centre, Malham, Saudi Arabia) the CPHI Middle East team hosted the Future Pharma Forum, to set the scene for an exciting new event for the pharma community, coming to Riya... -
News Pfizer maps out plans for developing new oncology therapeutics by 2030
Pfizer dilvulges plans to investors around growing their cancer portfolio, and the drugs they will be focusing on developing after their aquisition of Seagen in 2023. -
News Generics threat to Merck’s Bridion as Hikma seeks pre-patent expiry approval
Merck has disclosed they received notice from Hikma Pharmaceuticals for seeking a pre-patent expiry US FDA approval for Hikma’s generic version of Merck’s Bridion. -
News Bernie Sanders vs Big Pharma - the latest on drug price negotiations
In a hearing in front of the US Senate, three of the biggest pharmaceutical companies in America are challenged over exorbitant prescription drug prices, with Sanders claiming their actions are limiting the population's access to affordable healthc...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance